Compare AbbVie Inc (ABBV) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs L3Harris Technologies Inc — how do they compare? AbbVie Inc trades at $253.42 (market cap $449.91B), while L3Harris Technologies Inc trades at $292.29 (market cap $55.03B). The key difference: AbbVie Inc is far larger — about 8.2× L3Harris Technologies Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | LHX | |
|---|---|---|
Market Cap | $449.91B | $55.03B |
Sector | Health | Industrials |
52-Week High | $261.07 | $378.48 |
52-Week Low | $184.85 | $257.09 |
Enterprise Value | $513.38B | $65.80B |
Dividend Yield | 2.72% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
LHX trades at $295.4, down 2.21% today, with a bullish technical signal despite near-term overbought RSI conditions. The company reported strong Q1 2026 earnings, beating estimates with $5.7B revenue and a 1.4x book-to-bill ratio, boosting its backlog to a record $40.7B. Recent news highlights expansion in missile production and new defense contracts, supporting growth momentum.
LHX presents a favorable outlook with robust defense sector tailwinds and consistent earnings beats, though elevated valuation metrics and geopolitical risks warrant caution. Analyst consensus is strongly bullish with a $367.50 price target, implying significant upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
